SCOTIABANK GBM Maintains Probe Gold (PROBF) Outperform Recommendation

On Dec. 8, 2025 Scotiabank GBM reiterated an Outperform on Probe Gold (OTCPK:PROBF) with an average one‑year price target of $3.03 (range $2.64–$3.95), implying 218.53% upside from the $0.95 close; projected annual revenue is $0 million and non‑GAAP EPS is -$0.05. Institutional ownership has ticked up to 13.865 million shares across nine funds (one new owner quarter‑over‑quarter) and average fund weight rose to 0.64%, with major holders including ASA Gold (7.088M, 3.47%), EuroPac Gold (2.93M), Gabelli (1.65M) and an increased stake from John Hancock (495K). The note highlights pronounced analyst optimism and modestly rising fund interest, but the lack of revenue and negative earnings make the sizable price‑target upside speculative.

Analysis

Scotiabank GBM on December 8, 2025 reiterated an Outperform on Probe Gold (OTCPK:PROBF) and the consensus one‑year price target is $3.03 (range $2.64–$3.95), implying 218.53% upside from the latest close of $0.95. The article’s sentiment profile is moderately positive (score 0.3) but labeled speculative, reflecting analyst optimism rather than underlying cash‑flow metrics.

Reported fundamentals are weak: projected annual revenue is $0MM and projected non‑GAAP EPS is -$0.05, a clear disconnect between valuation upside and current operating performance. The market‑impact score is low (0.25), suggesting the price target relies on future exploration, development or financing milestones rather than immediate financial improvement.

Institutional positioning shows modest incremental support: nine funds hold 13.865 million shares (up 0.43% in three months) and average fund weight rose to 0.64% (up 13.05%), with concentration in ASA Gold & Precious Metals (7.088M, 3.47%) and a notable allocation increase from John Hancock (495K, allocation +75.31%). Small reductions by EuroPac and Franklin indicate mixed fund conviction beneath the headline analyst call.

The takeaway for investors is that the analyst upside is material but speculative absent revenue or positive EPS revisions; the stock’s OTC listing and concentrated holdings make upside contingent on discrete operational or financing catalysts and warrants risk‑managed exposure.

Key Decisions for Investors

• Limit exposure to a small, size‑constrained speculative position and avoid increasing core allocation until the company reports revenue generation or positive EPS revisions.
• Monitor upcoming filings, assay/drilling/operational announcements and analyst coverage changes closely, and treat additional institutional inflows—particularly further increases from John Hancock—as potential validation of the price‑target thesis.
• If maintaining a position, implement strict risk controls such as predefined stop limits or hedges and be prepared to exit or reduce exposure if catalysts do not materialize within the analyst time horizon.